Ketamine
Established medicineAlso known as 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone, DL-ketamine+9 more
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone, DL-ketamine, Ketalar, Ketaset, Zetamine, (+-)-Ketamine, (±)-ketamine, Ketamina, Kétamine, Ketamine Hydrochloride, Ketaminum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Health, Defense Secretaries Pave Way for Ketamine Drug
Ketamine Infusions Shows Benefit in Bipolar Depression
Surgeon Indicted Over Shootout; $15M Asthma Death Settlement; Ketamine Doc Suspended
Ketamine Showed Antidepressive Effects in Refractory Bipolar Depression
NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Biological psychiatry4
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology4
- Anesthesiology3
- Molecular psychiatry3
- Anesthesia and analgesia2
- CNS neuroscience & therapeutics2
- Zarate CA Jr5
- Nugent AC4
- Ballard ED3
- Charney DS3
- Park LT3
- Akeju O2
- Brown EN2
- Brutsche NE2
- National Institute of Mental Health7
- Yale School of Medicine3
- Division of Clinical Neuroscience2
- Harvard Medical School2
- Laboratory of Neurotherapeutics2
- Massachusetts General Hospital2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Ketamine in the shared literature.
Studied across 7 of the same disease areas as Ketamine in the shared literature.
Studied across 3 of the same disease areas as Ketamine in the shared literature.
Studied across 3 of the same disease areas as Ketamine in the shared literature.
Studied across 3 of the same disease areas as Ketamine in the shared literature.
Studied across 3 of the same disease areas as Ketamine in the shared literature.
Studied across 3 of the same disease areas as Ketamine in the shared literature.
Studied across 2 of the same disease areas as Ketamine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials